Synthetic catalytic scavenger - Eukarion/IsoTis

Drug Profile

Synthetic catalytic scavenger - Eukarion/IsoTis

Alternative Names: Oxyscav; Reactive oxygen species scavenger - Eukarion/IsoTis

Latest Information Update: 15 Jan 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eukarion
  • Developer IsoTis SA
  • Class Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Radiation-induced skin damage

Most Recent Events

  • 08 Jan 2003 Modex Therapeutics has merged with IsoTis NV to form IsoTis SA
  • 07 Jan 2003 Discontinued - Preclinical for Radiation-induced skin damage in USA (Topical)
  • 17 Jan 2002 Modex Therapeutics has submitted a pre-IND package to the US FDA for Oxyscav in patients with breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top